Print ISSN: 2395-1443
Online ISSN: 2395-1451
CODEN : IJCEKF
Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfil our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free access (Open Access) to its content, which is likely to attract more readers and citations of articles published in IJCEO. Manuscripts must be prepared in more...Original Article
Author Details :
Volume : 5, Issue : 4, Year : 2019
Article Page : 442-446
https://doi.org/10.18231/j.ijceo.2019.106
Abstract
The main objective of this study was to evaluate the safety and efficacy profile of intralesional triamcinolone
acetonide (TA) injection for the treatment of primary chalazion.
We study included 20 patients in our study who had chalazion persis ting for nearly one month. All of
them did not respond to applied topical antimicrobial therapy. These patients were taking intralesional
triamcinolone injection as a mode of treatment of chalazion (dosage of 2 – 4 mg).
Patients were being evaluated 1 day, 14 days and 1 month after intralesional triamcinolone injection. We
noted that treating chalazion with intralesional triamcinolone injection was much more convenient for
patients, less time consuming to treat and did not require extra topical antimicrobial treatment.
Keywords: Chalazion, Triamcinolone injection, Efficacy of therapy.
How to cite : Paul G, Kumar D, Ahmed T, A study on intralesional triamcinolone acetonide injection- A non-surgicaltechnique of treatment of chalazion. Indian J Clin Exp Ophthalmol 2019;5(4):442-446
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.